Published Erratum
doi: 10.1038/s41586-022-05632-x.
Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
Christopher P Vellano #
1
, Michael G White #
2
, Miles C Andrews #
2
3
, Manoj Chelvanambi #
2
, Russell G Witt #
2
, Joseph R Daniele
1
, Mark Titus
4
, Jennifer L McQuade
5
, Fabio Conforti
6
, Elizabeth M Burton
2
, Matthew J Lastrapes
2
, Gabriel Ologun
2
7
, Alexandria P Cogdill
2
8
, Golnaz Morad
2
, Peter Prieto
2
9
, Alexander J Lazar
10
11
12
, Yanshuo Chu
11
, Guangchun Han
11
, M A Wadud Khan
2
, Beth Helmink
2
13
, Michael A Davies
5
, Rodabe N Amaria
5
, Jeffrey J Kovacs
1
, Scott E Woodman
11
, Sapna Patel
5
, Patrick Hwu
5
14
, Michael Peoples
1
, Jeffrey E Lee
2
, Zachary A Cooper
2
15
, Haifeng Zhu
11
, Guang Gao
1
, Hiya Banerjee
16
, Mike Lau
17
, Jeffrey E Gershenwald
2
, Anthony Lucci
2
, Emily Z Keung
2
, Merrick I Ross
2
, Laura Pala
6
, Eleonora Pagan
18
, Rossana Lazcano Segura
12
, Qian Liu
19
, Mikayla S Borthwick
20
, Eric Lau
19
, Melinda S Yates
20
, Shannon N Westin
20
, Khalida Wani
12
, Michael T Tetzlaff
10
21
, Lauren E Haydu
2
, Mikhila Mahendra
1
, XiaoYan Ma
1
, Christopher Logothetis
4
, Zachary Kulstad
2
, Sarah Johnson
2
, Courtney W Hudgens
12
, Ningping Feng
1
, Lorenzo Federico
1
, Georgina V Long
22
, P Andrew Futreal
11
, Swathi Arur
23
, Hussein A Tawbi
5
, Amy E Moran
24
, Linghua Wang
11
, Timothy P Heffernan
25
, Joseph R Marszalek
26
, Jennifer A Wargo
27
28
Affiliations
Affiliations
- 1 TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- 2 Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- 3 Department of Medicine, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
- 4 Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- 5 Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- 6 Division of Melanoma, Sarcoma, and Rare Tumors, European Institute of Oncology, IRCCS, Milan, Italy.
- 7 Department of Surgery, Guthrie Courtland Medical Center, Courtland, NY, USA.
- 8 Immunai, New York, NY, USA.
- 9 Department of Surgery, University of Rochester, Rochester, NY, USA.
- 10 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- 11 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- 12 Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- 13 Department of Surgery, Washington University in St Louis, St Louis, MO, USA.
- 14 Moffitt Cancer Center, Tampa, FL, USA.
- 15 AstraZeneca, Gaithersburg, MD, USA.
- 16 Clinical Development and Analytics, Novartis Pharmaceuticals, East Hanover, NJ, USA.
- 17 Novartis Pharma, Basel, Switzerland.
- 18 Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy.
- 19 Department of Tumor Biology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
- 20 Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- 21 Department of Pathology, University of California, San Francisco, CA, USA.
- 22 Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia.
- 23 Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- 24 Cell, Development & Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
- 25 TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. TPHeffernan@mdanderson.org.
- 26 TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jrmarszalek@mdanderson.org.
- 27 Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jwargo@mdanderson.org.
- 28 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jwargo@mdanderson.org.
# Contributed equally.
- PMID: 36627494
- DOI: 10.1038/s41586-022-05632-x
Item in Clipboard
Published Erratum
Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
Christopher P Vellano et al.
Nature.
2023 Jan.
Display options
Format
doi: 10.1038/s41586-022-05632-x.
Authors
Christopher P Vellano #
1
, Michael G White #
2
, Miles C Andrews #
2
3
, Manoj Chelvanambi #
2
, Russell G Witt #
2
, Joseph R Daniele
1
, Mark Titus
4
, Jennifer L McQuade
5
, Fabio Conforti
6
, Elizabeth M Burton
2
, Matthew J Lastrapes
2
, Gabriel Ologun
2
7
, Alexandria P Cogdill
2
8
, Golnaz Morad
2
, Peter Prieto
2
9
, Alexander J Lazar
10
11
12
, Yanshuo Chu
11
, Guangchun Han
11
, M A Wadud Khan
2
, Beth Helmink
2
13
, Michael A Davies
5
, Rodabe N Amaria
5
, Jeffrey J Kovacs
1
, Scott E Woodman
11
, Sapna Patel
5
, Patrick Hwu
5
14
, Michael Peoples
1
, Jeffrey E Lee
2
, Zachary A Cooper
2
15
, Haifeng Zhu
11
, Guang Gao
1
, Hiya Banerjee
16
, Mike Lau
17
, Jeffrey E Gershenwald
2
, Anthony Lucci
2
, Emily Z Keung
2
, Merrick I Ross
2
, Laura Pala
6
, Eleonora Pagan
18
, Rossana Lazcano Segura
12
, Qian Liu
19
, Mikayla S Borthwick
20
, Eric Lau
19
, Melinda S Yates
20
, Shannon N Westin
20
, Khalida Wani
12
, Michael T Tetzlaff
10
21
, Lauren E Haydu
2
, Mikhila Mahendra
1
, XiaoYan Ma
1
, Christopher Logothetis
4
, Zachary Kulstad
2
, Sarah Johnson
2
, Courtney W Hudgens
12
, Ningping Feng
1
, Lorenzo Federico
1
, Georgina V Long
22
, P Andrew Futreal
11
, Swathi Arur
23
, Hussein A Tawbi
5
, Amy E Moran
24
, Linghua Wang
11
, Timothy P Heffernan
25
, Joseph R Marszalek
26
, Jennifer A Wargo
27
28
Affiliations
- 1 TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- 2 Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- 3 Department of Medicine, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
- 4 Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- 5 Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- 6 Division of Melanoma, Sarcoma, and Rare Tumors, European Institute of Oncology, IRCCS, Milan, Italy.
- 7 Department of Surgery, Guthrie Courtland Medical Center, Courtland, NY, USA.
- 8 Immunai, New York, NY, USA.
- 9 Department of Surgery, University of Rochester, Rochester, NY, USA.
- 10 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- 11 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- 12 Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- 13 Department of Surgery, Washington University in St Louis, St Louis, MO, USA.
- 14 Moffitt Cancer Center, Tampa, FL, USA.
- 15 AstraZeneca, Gaithersburg, MD, USA.
- 16 Clinical Development and Analytics, Novartis Pharmaceuticals, East Hanover, NJ, USA.
- 17 Novartis Pharma, Basel, Switzerland.
- 18 Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy.
- 19 Department of Tumor Biology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
- 20 Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- 21 Department of Pathology, University of California, San Francisco, CA, USA.
- 22 Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia.
- 23 Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- 24 Cell, Development & Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
- 25 TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. TPHeffernan@mdanderson.org.
- 26 TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jrmarszalek@mdanderson.org.
- 27 Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jwargo@mdanderson.org.
- 28 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jwargo@mdanderson.org.
# Contributed equally.
- PMID: 36627494
- DOI: 10.1038/s41586-022-05632-x
Item in Clipboard
Display options
Format
No abstract available
Erratum for
-
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA. Vellano CP, et al. Nature. 2022 Jun;606(7915):797-803. doi: 10.1038/s41586-022-04833-8. Epub 2022 Jun 15. Nature. 2022. PMID: 35705814 Free PMC article.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
